Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axalimogene filolisbac - Ayala Pharmaceuticals

Next Previous
Drug Profile

Axalimogene filolisbac - Ayala Pharmaceuticals

Alternative Names: ADXS HPV; ADXS-11-001; ADXS11-001-vaccine; Anal-cancer-vaccine- Ayala Pharmaceuticals; AXAL; Cervical cancer vaccine - Ayala Pharmaceuticals; Head and neck cancer vaccine - Ayala Pharmaceuticals; Listeria cancer vaccine - Ayala Pharmaceuticals; Listeria monocytogenes vaccine live attenuated - Ayala Pharmaceuticals; Live attenuated listeria monocytogenes vaccine - Ayala Pharmaceuticals; Lm-Listeriolysin-O-fetal liver kinase-1; Lm-LLO-E7; Lm-LLO-E7 vaccine; Lovaxin-C; NSC-752718; Raligize

Latest Information Update: 27 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advaxis
  • Developer Advaxis; Ayala Pharmaceuticals; Brown University Medical School; Cancer Research UK; Gynecologic Oncology Group; Icahn School of Medicine at Mount Sinai; MedImmune
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action Gene transference; Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cervical cancer; Head and neck cancer; Anal cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Cervical cancer

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Anal cancer; Oropharyngeal cancer
  • Phase I/II Head and neck cancer
  • Discontinued Cervical intraepithelial neoplasia

Most Recent Events

  • 19 Dec 2023 Advaxis withdrew a phase II trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA and Taiwan, prior to enrolment (NCT02531854)
  • 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
  • 09 Mar 2022 Phase III development is still ongoing for Cervical cancer in Argentina, Brazil, Canada, Chile, Malaysia, Mexico, Poland, Russia, Serbia, South Korea, Spain, Taiwan, USA, Ukraine
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top